长效FSH类似物N02对比重组FSH在中国女性中的III期试验
这项双盲多中心III期试验纳入474名20-39岁卵巢储备正常的中国女性,按1:1随机接受单次皮下注射corifollitropin alfa N02(100/150 μg)或每日重组FSH(150/225 IU)促排卵。N02组获卵数12.1枚,非劣效于rFSH组的10.9枚(估计差值1.2,95%CI 0.23-2.12),安全性特征相似,为简化促排卵方案提供了选择。
要点
- N02单次给药获卵数非劣效于每日rFSH(12.1 vs 10.9枚)。
- 两组临床妊娠率46.3% vs 51.1%,持续妊娠率38.8% vs 44.3%。
- OHSS发生率3.8% vs 2.5%,治疗相关不良事件15.2% vs 11.0%。
核心结论
- 单次corifollitropin alfa N02在获卵数上非劣效于每日rFSH,安全性相似,为中国卵巢储备正常女性提供简化促排卵方案。
研究设计与样本
- 双盲、多中心III期试验(NCT06091436),474名20-39岁卵巢储备正常中国女性按1:1随机分组。
- N02组238例接受单次皮下100/150 μg,rFSH组236例每日150/225 IU,第8天起个体化每日rFSH。
- 主要目标为获卵数非劣效,非劣效界值-3。
主要发现
- N02组平均获卵12.1枚,rFSH组10.9枚,估计差值1.2(95%CI 0.23-2.12),达到非劣效。
- 临床妊娠率N02组46.3%、rFSH组51.1%;持续妊娠率分别为38.8%和44.3%。
- OHSS发生率N02组3.8%、rFSH组2.5%;治疗相关不良事件分别为15.2%和11.0%。
- II期与III期汇总数据显示12个月新生儿出生缺陷率N02组7.6%、rFSH组12.0%。
- N02组3.0%检出抗药抗体,无临床影响。
关键数值与推荐
- 获卵数非劣效界值为-3,估计差值1.2(95%CI 0.23-2.12)。
- N02剂量100/150 μg单次皮下注射;rFSH 150/225 IU每日,第8天起个体化。
临床怎么用
- 对卵巢储备正常的中国女性,可考虑单次N02替代每日rFSH以简化促排卵流程。
- 用药后需常规监测OHSS及治疗相关不良事件,抗体检测无临床影响。
局限性
- 新生儿结局来自II期与III期汇总数据,并非本试验单独报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What is the efficacy and safety of corifollitropin alfa N02, a long-acting FSH analogue, in comparison with daily recombinant FSH (rFSH) for ovarian stimulation in Chinese women? DESIGN: In this double-blind, multicentre trial (NCT06091436), 474 women aged 20-39 years with a normal ovarian reserve were randomized 1:1 to a single subcutaneous dose of corifollitropin alfa N02 (100/150 μg; n = 238) or daily rFSH (150/225 IU; n = 236) for the first week of stimulation, followed by individualized daily rFSH from day 8. The primary objective was non-inferiority in the number of oocytes retrieved (margin -3). RESULTS: The corifollitropin alfa N02 group demonstrated non-inferiority, with a mean of 12.1 oocytes retrieved versus 10.9 in the daily rFSH group (estimated difference 1.2, 95% CI 0.23-2.12). The clinical pregnancy rate was 46.3% in the corifollitropin alfa N02 group and 51.1% in the daily rFSH group, and the ongoing pregnancy rate was 38.8% and 44.3%, respectively. Safety profiles were similar: ovarian hyperstimulation syndrome occurred in 3.8% of women in the corifollitropin alfa N02 group and 2.5% of women in the daily rFSH group, and treatment-related adverse events occurred in 15.2% and 11.0% of women, respectively. Pooled data from phase 2 and 3 trials reported neonatal outcomes at 12 months, with a birth defect rate of 7.6% for the corifollitropin alfa N02 group and 12.0% the daily rFSH group. Anti-drug antibodies were detected in 3.0% of women in the corifollitropin alfa N02 group without clinical impact. CONCLUSIONS: A single dose of corifollitropin alfa N02 was non-inferior to daily rFSH in terms of oocyte yield, with similar safety, offering a simplified ovarian stimulation alternative for Chinese women with a normal ovarian reserve.
引用
- Li T, Chen X, Sun Y, et al. Corifollitropin alfa N02 versus recombinant FSH for ovarian stimulation: a phase 3 trial and safety study in Chinese women. Reprod Biomed Online. 2026. PMID: 42462332. doi:10.1016/j.rbmo.2026.105822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。